Citations

Clear

1526 citation(s) found for "Sun, Yu".

Application of a multiplex urinalysis test for the prediction of intravesical BCG treatment response: A pilot study
Murakami, Kaoru, Kamat, Ashish M., Dai, Yunfeng, Pagano, Ian, Chen, Runpu, Sun, Yijun, Gupta, Amit, Goodison, Steve, Rosser, Charles J., Furuya, Hideki, Furuya, Hideki , Furuya, Hideki , Murakami, Kaoru, Kamat, Ashish M., Dai, Yunfeng, Pagano, Ian, Chen, Runpu, Sun, Yijun, Gupta, Amit, Goodison, Steve, Rosser, Charles J., Furuya, Hideki

Mayo Clinic

Cancer Biomarkers | September 7, 2021 | Volume: 33 | Issue: 1 | Pages: 151-157

10.3233/cbm-210221 | PMID 34511488 Get It

BACKGROUND: Intravesical Bacillus Calmette-Guerin (BCG), a live attenuated tuberculosis vaccine that acts as a non-specific immune system stimulant, is the most effective adjuvant treatment for patients with intermediate or high-risk non-muscle-invasive bladder cancer (NMIBC). However, to date, there are no reliable tests that are predictive of BCG treatment response. In this study, we evaluated the performance of OncuriaTM, a bladder cancer detection test, to predict response to intravesical BCG. METHODS: OncuriaTM data was evaluated in voided urine samples obtained from a prospectively collected cohort of 64 subjects with intermediate or high risk NMIBC prior to treatment with intravesical BCG. The OncuriaTM test, which measures 10 cancer-associated biomarkers was performed in an independent clinical laboratory. The ability of the test to identify those patients in whom BCG is ineffective against tumor recurrence was tested. Predictive models were derived using supervised learning and cross-validation analyses. Model performance was assessed using ROC curves. RESULTS: Pre-treatment urinary concentrations of MMP9, VEGFA, CA9, SDC1, PAI1, APOE, A1AT, ANG and MMP10 were increased in patients who developed disease recurrence. A combinatorial predictive model of treatment outcome achieved an AUROC 0.89 [95% CI: 0.80–0.99], outperforming any single biomarker, with a test sensitivity of 81.8% and a specificity of 84.9%. Hazard ratio analysis revealed that patients with higher urinary levels of ANG, CA9 and MMP10 had a significantly higher risk of disease recurrence. CONCLUSIONS: Monitoring the urinary levels of a cancer-associated biomarker panel enabled the discrimination of patients who did not respond to intravesical BCG therapy. With further study, the multiplex OncuriaTM test may be applicable for the clinical evaluation of bladder cancer patients considering intravesical BCG treatment.
Coronary Microcirculatory Dysfunction and Acute Cellular Rejection After Heart Transplantation
Lee, Joo Myung , Choi, Ki Hong, Choi, Jin‐Oh , Shin, Doosup , Park, Yoonjee , Kim, Juwon, Lee, Seung Hun , Kim, Darae, Yang, Jeong Hoon, Cho, Yang Hyun, Sung, Kiick, Choi, Ji Yeon, Park, Meesoon, Kim, Jung-Sun, Park, Taek Kyu, Gwon, Hyeon-Cheol , Oh, Jae K., Jeon, Eun-Seok, Song, Young Bin , Hahn, Joo‐Yong , Choi, Seung-Hyuk , Gwon, Hyeon-Cheol , Shin, Doosup , Lee, Joo Myung , Choi, Ki Hong, Choi, Jin-Oh , Park, Yoonjee , Kim, Juwon, Lee, Seung Hun , Kim, Darae, Yang, Jeong Hoon, Cho, Yang Hyun, Sung, Kiick, Choi, Ji Yeon, Park, Meesoon, Kim, Jung-Sun, Park, Taek Kyu, Oh, Jae K., Jeon, Eun-Seok

Mayo Clinic

Circulation | September 3, 2021 | Volume: 144 | Issue: 18 | Pages: 1459-1472

10.1161/circulationaha.121.056158 | PMID 34474597 Get It

Background: Acute cellular rejection is a major determinant of mortality and retransplantation after heart transplantation. We sought to evaluate the prognostic implications of coronary microcirculatory dysfunction assessed by index of microcirculatory resistance (IMR) for the risk of acute cellular rejection after heart transplantation. Methods: The present study prospectively enrolled 154 heart transplant recipients who underwent scheduled coronary angiography and invasive coronary physiological assessment 1 month after transplantation. IMR is microcirculatory resistance under maximal hyperemia. By measuring hyperemic mean transit time using 3 injections (4 mL each) of room-temperature saline under maximal hyperemia, IMR was calculated as hyperemic distal coronary pressure×hyperemic mean transit time. The primary end point was biopsy-proven acute cellular rejection of grade ≥2R during 2 years of follow-up after transplantation and was compared by using multivariable Cox proportional hazards regression according to IMR. The incremental prognostic value of IMR, in addition to the model with clinical factors, was evaluated by comparison of C-index, net reclassification index, and integrated discrimination index. Results: The mean age of recipients was 51.2±13.1 years (81.2% male), and the cumulative incidence of acute cellular rejection was 19.0% at 2 years. Patients with acute cellular rejection had significantly higher IMR values at 1 month than those without acute cellular rejection (23.1±8.6 versus 16.8±11.1, P =0.002). IMR was significantly associated with the risk of acute cellular rejection (per 5-U increase: adjusted hazard ratio, 1.18 [95% CI, 1.04–1.34], P =0.011) and the optimal cutoff value of IMR to predict acute cellular rejection was 15. Patients with IMR≥15 showed significantly higher risk of acute cellular rejection than those with IMR<15 (34.4% versus 3.8%; adjusted hazard ratio, 15.3 [95% CI 3.6–65.7], P <0.001). Addition of IMR to clinical variables showed significantly higher discriminant and reclassification ability for risk of acute cellular rejection (C-index 0.87 versus 0.74, P <0.001; net reclassification index 1.05, P <0.001; integrated discrimination index 0.20, P <0.001). Conclusions: Coronary microcirculatory dysfunction assessed by IMR measured early after heart transplantation showed significant association with the risk of acute cellular rejection. In addition to surveillance endomyocardial biopsy, early stratification using IMR could be a clinically useful tool to identify patients at higher risk of future acute cellular rejection after heart transplantation. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02798731.
SNX27-FERM-SNX1 complex structure rationalizes divergent trafficking pathways by SNX17 and SNX27
Yong, Xin, Ham, Hyoungjun , Liu, Zhe , Ren, Jie , Zhang, Zhen , Zhou, Yifei, Yang, Qin , Mo, Xianming , Billadeau, Daniel D. , Jia, Da , Yang, Qin , Mo, Xianming , Hu, Junjie , Jia, Da , Yong, Xin, Zhao, Lin , Hu, Wenfeng , Sun, Qingxiang

Mayo Clinic

Proceedings of the National Academy of Sciences | August 30, 2021 | Volume: 118 | Issue: 36 | Pages: No page available

10.1073/pnas.2105510118 | PMID 34462354 Get It

Significance The sorting nexin proteins are critical for endosomal trafficking and signaling. SNX17 and SNX27 are two SNX proteins displaying high similarity in domain structure, including a common FERM domain; however, they mediate distinct endocytic recycling pathways. We now solve this mystery by demonstrating that the FERM domains of SNX17 and SNX27 have different functions. Whereas the FERM domain of SNX17 recognizes the NPxY/NxxY motif, the same domain in SNX27 binds to a novel “DLF” motif within the N termini of SNX1/2. The interaction between SNX27 and SNX1/2 not only helps efficient retrieval of multiple cargoes but also promotes endosomal recruitment of SNX27. We further demonstrate that the SNX27–SNX1/2 interaction is crucial to neuronal growth and brain development in zebrafish.
Peripheral nerve block anesthesia/analgesia for patients undergoing primary hip and knee arthroplasty: recommendations from the International Consensus on Anesthesia-Related Outcomes after Surgery (ICAROS) group based on a systematic review and meta-analys
Memtsoudis, Stavros G. , Cozowicz, Crispiana , Bekeris, Janis, Bekere, Dace, Liu, Jiabin , Soffin, Ellen M. , Mariano, Edward R. , Johnson, Rebecca L. , Go, George , Hargett, Mary J. , Lee, Bradley H. , Wendel, Pamela , Brouillette, Mark , Kim, Sang Jo, Baaklini, Lila , Wetmore, Douglas S., Hong, Genewoo , Goto, Rie , Jivanelli, Bridget , Athanassoglou, Vassilis , Αrgyra, Eriphili, Barrington, Michael J. , Borgeat, Alain , El‐Boghdadly, Kariem , Elkassabany, Nabil , Gautier, Philippe , Gerner, Peter, Valle, Alejandro González Della , Goytizolo, Enrique A. , Guo, Zhenggang , Hogg, Rosemary , Kehlet, Henrik , Kessler, Paul, Lavand"homme, Patricia, Macfarlane, Alan , McIsaac, Dan , Neal, Joseph M. , Peng, Philip , Pichler, Lukas, Poultsides, Lazaros, Sites, Brian D. , Stundner, Ottokar , Sun, Eric, Viscusi, Eugene R. , Votta‐Velis, E. Gina, YaDeau, Jacques T. , Sharrock, Nigel E. , Barrington, Michael John , El-Boghdadly, K , Elkassabany, Nabil M , Kopp, Sandra , Mantilla, Carlos, Neal, Joseph M , Poeran, Jashvant , Schwenk, Eric S , Stundner, Ottokar , Viscusi, Eugene , Wu, Christopher L , Mariano, Edward R , Johnson, Rebecca L , Soffin, Ellen M , Macfarlane, Alan James Robert , Andrés, José De , Kessler, Paul, Kopp, Sandra L. , Lavand"homme, Patricia, MacLean, Catherine H. , Mantilla, Carlos B. , McLawhorn, Alexander S. , Parks, Michael L. , Parvizi, Javad , Schwenk, Eric S.

Mayo Clinic

Regional Anesthesia & Pain Medicine | August 25, 2021 | Volume: 46 | Issue: 11 | Pages: 971-985

10.1136/rapm-2021-102750 | PMID 34433647 Get It

Background Evidence-based international expert consensus regarding the impact of peripheral nerve block (PNB) use in total hip/knee arthroplasty surgery. Methods A systematic review and meta-analysis: randomized controlled and observational studies investigating the impact of PNB utilization on major complications, including mortality, cardiac, pulmonary, gastrointestinal, renal, thromboembolic, neurologic, infectious, and bleeding complications. Medline, PubMed, Embase, and Cochrane Library including Cochrane Database of Systematic Reviews, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, were queried from 1946 to August 4, 2020. The Grading of Recommendations Assessment, Development, and Evaluation approach was used to assess evidence quality and for the development of recommendations. Results Analysis of 122 studies revealed that PNB use (compared with no use) was associated with lower ORs for (OR with 95% CIs) for numerous complications (total hip and knee arthroplasties (THA/TKA), respectively): cognitive dysfunction (OR 0.30, 95% CI 0.17 to 0.53/OR 0.52, 95% CI 0.34 to 0.80), respiratory failure (OR 0.36, 95% CI 0.17 to 0.74/OR 0.37, 95% CI 0.18 to 0.75), cardiac complications (OR 0.84, 95% CI 0.76 to 0.93/OR 0.83, 95% CI 0.79 to 0.86), surgical site infections (OR 0.55 95% CI 0.47 to 0.64/OR 0.86 95% CI 0.80 to 0.91), thromboembolism (OR 0.74, 95% CI 0.58 to 0.96/OR 0.90, 95% CI 0.84 to 0.96) and blood transfusion (OR 0.84, 95% CI 0.83 to 0.86/OR 0.91, 95% CI 0.90 to 0.92). Conclusions Based on the current body of evidence, the consensus group recommends PNB use in THA/TKA for improved outcomes. Recommendation: PNB use is recommended for patients undergoing THA and TKA except when contraindications preclude their use. Furthermore, the alignment of provider skills and practice location resources needs to be ensured. Evidence level: moderate; recommendation: strong.
Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19
Shah, Pankil , Rubinstein, Samuel M. , Joyner, Michael J. , Choueiri, Toni K. , Flora, Daniel , Gulati, Anthony P., Koshkin, Vadim S. , Papadopoulos, Esperanza B. , Robilotti, Elizabeth , Su, Christopher , Wulff‐Burchfield, Elizabeth , Xie, Zhuoer , Yu, Peter Paul , Mishra, Sanjay , Senefeld, Jonathon W. , Shah, Dimpy P. , Verma, Amit , Gartrell, Benjamin A. , Ohri, Nitin , Butt, Omar H. , Campian, Jian , Fiala, Mark A. , Monahan, Ryan, Bohachek, Pamela, Mundt, Daniel , Streckfuss, Mitrianna, Tadesse, Eyob, Lammers, Philip E. , Revankar, Sanjay G. , Khan, Hina, Prete, Salvatore A. Del , Angevine, Anne H., Bär, Michael , Lo, KM Steve, Stratton, Jamie , Weinstein, Paul L., García, Jorge A. , Nakayama, John , Gupta, Shilpa , Ahluwalia, Manmeet S. , Dawsey, Scott J. , Nizam, Amanda , Lemmon, Christopher A. , Hoppenot, Claire , Bakouny, Ziad , Bouchard, Gabrielle, Busser, Fiona, Conners, Jean M, Curran, Catherine , Demetri, George D., Kelleher, Kaitlin M. , Shaw, Grace, Nuzzo, Pier Vitale , Zon, Rebecca L. , Zhang, Tian , Grivas, Petros , Lynch, Ryan C. , Schweizer, Michael T. , Tachiki, Lisa ML, Vinayak, Shaveta , Wagner, Michael J. , Yeh, Albert C. , Goyal, Sharad , Clément, Jessica , Daher, Ahmad , Dailey, Mark E., Hsu, Emily , Menendez, Alvaro G. , Rathmann, Joerg, Serrano, Oscar K. , Jayaraj, Asha, Accordino, Melissa , Mushtaq, Sarah, Bernicker, Eric , Deeken, John F. , Shafer, Danielle , Lewis, Mark A. , Rhodes, Terence D., Gill, David , Low, Clarke A., Nagle, Sarah , Hayes‐Lattin, Brandon , Nemecek, Eneida R. , Zaren, Howard A. , Smith, Stephanie J., Akhtari, Mojtaba, Lau, Eric , Reeves, Mark E. , Elms, Destry, Altman, Jessica K. , Gurley, Michael, Mulcahy, Mary F. , Kulkarni, Amit , Shah, Surbhi, Rosovsky, Rachel , Reynolds, Kerry L. , Bardia, Aditya , Gainor, Justin F. , Zubiri, Leyre , Bonnen, Mark , Mahadevan, Daruka , Salazar, Mary, Belenkaya, Rimma , Riely, Gregory J. , Faller, Bryan A. , McKay, Rana R. , Ajmera, Archana , Cabal, Angelo , Shaya, Justin , Weissmann, Lisa B., Jani, Chinmay , Chen, James L. , Jhawar, Sachin R, Lustberg, Maryam B. , Pillainayagam, Clement, Wall, Sarah , Williams, Nicole , Karivedu, Vidhya , Addison, Daniel , Menon, Harry, Rovito, Marc A., Elshoury, Amro, Shah, Mansi , Mahmood, Sana , Mico, Vasil, Rivera, Andrea Verghese, Miller, Chaim , Cabebe, Elwyn C., Glover, Michael , Jha, Alokkumar , Schapira, Lidia , Shah, Sumit , Subbiah, Suki , Logan, Barbara, Lopes, Gilberto , Russell, Karen , Stith, Brittany, Smits, Melissa, Edwin, Natasha, Chism, David D. , Owenby, Susie, Doroshow, Deborah B. , Galsky, Matthew D. , Zhu, Huili , Fu, Julie , Patel, Kanishka G. , Riess, Jonathan W. , Kwon, Daniel H. , Islam, Jessica Y. , Ahmad, Syed A. , Grover, Punita , Kharofa, Jordan , Marcum, Michelle, Park, Cathleen, Geiger, Christopher L., Bishnoi, Rohit , Feldman, Lawrence , Hoskins, Kent , Gantt, Gerald, Khan, Mahir, Nguyen, Ryan H, Schwartz, Candice, Venepalli, Neeta K. , Kasi, Anup , Fecher, Leslie A. , Mavromatis, Blanche H., Bijjula, Ragneel R., Cheng, Alex , French, Benjamin , Gillaspie, Erin A. , Hennessy, Cassandra , Johnson, Douglas B. , Reid, Sonya , Slosky, David, Solórzano, Carmen C. , Vega-Luna, Karen, Enriquez, Kyle T. , Sun, Tianyi , Carducci, Theresa M., Puc, Matthew , Loon, Susan Van, Goldsmith, Karen J., Rice, Robert, Cabalona, Wilhelmina D., Pilar, Christine, McCollough, Briana Barrow, Peddi, Prakash , Rosen, L, Bilen, Mehmet Asım , Ravindranathan, Deepak , LoRusso, Patricia , Masters, Tyler, Choueiri, Toni K , Bakouny, Ziad , Mishra, Sanjay , Yeh, Albert C , Xie, Zhuoer , Zubiri, Leyre , Su, Christopher , Fiala, Mark A , Joyner, Michael J , Senefeld, Jonathon W , Ahluwalia, Manmeet S , Lustberg, Maryam , Thompson, Michael A. , Henderson, Jeffrey P. , Griffiths, Elizabeth A. , Hwang, Clara , Warner, Jeremy L. , Halmos, Balázs , Goel, Sanjay , Sica, Roberto Alejandro , Thakkar, Astha , Stockerl‐Goldstein, Keith , Zhou, Alice Y. , Tadesse, Eyob, Panagiotou, Orestis A. , Egan, Pamela , Farmakiotis, Dimitrios , Olszewski, Adam J. , Loaiza‐Bonilla, Arturo , Bar, Michael H, Lo, K. M. Steve, Caimi, Paolo F. , Barnholtz‐Sloan, Jill S. , Pennell, Nathan A , Li, Ang , Giordano, Antonio , Nohria, Anju , Schmidt, Andrew , Van Allen, Eliezer M , Xu, Wenxin Vincent , Halabi, Susan , Lyman, Gary H , Graber, Jerome J. , Khaki, Ali Raza , Loggers, Elizabeth T , Nakasone, Elizabeth S. , Tachiki, Lisa M, Gatson, Na Tosha , Huynh‐Le, Minh‐Phuong , Rosenstein, Lori J. , Elias, Rawad , Gadgeel, Shirish M. , Hawley, Jessica E. , Hershman, Dawn L. , Bhutani, Divaya , Schwartz, Gary K. , Reuben, Daniel Y. , McWeeney, Shannon K. , Nagaraj, Gayathri , Berg, Stephanie , Morgans, Alicia K. , Wehbe, Firas , Durbin, Eric B. , Nelson, Heather H. , Boland, Genevieve M. , Hálfdánarson, Þorvarður R. , Bekaii‐Saab, Tanios , Desai, Aakash , Mesa, Ruben A. , Ramirez, Amelie G , Philip, John , Gatti-Mays, Margaret Elena , Jhawar, Sachin R, Palmer, Joshua D. , Stover, Daniel G. , Joshi, Monika , Jabbour, Salma K , Bashir, Babar , McNair, Christopher M. , Wu, Julie , Kloecker, Goetz Hans , Fazio, Alyson, Kumar, Vaibhav , Wood, William A. , Gulati, Shuchi , Wise-Draper, Trisha Michel , Bowles, Daniel W. , Markham, Merry Jennifer , Shah, Chintan , Acoba, Jared David , Rho, Young Soo, Nguyen, Ryan H, Pasquinelli, Mary M. , Vikas, Praveen , Friese, Christopher R. , Zaman, Qamar U, Davis, Elizabeth J. , Hausrath, Daniel J. , Hsu, Chih–Yuan , Li, Xuanyi , Rini, Brian I. , Shyr, Yu , Tucker, Matthew D. , Wang, Lucy Lu , Hafez, Navid , Herbst, Roy S. , Stratton, Catherine

Mayo Clinic

JAMA Oncology | August 19, 2021 | Volume: 7 | Issue: 8 | Pages: 1167

10.1001/jamaoncol.2021.1799 | PMID 34137799 Get It

CERTAIN Program: Logic Model for System Level Planning and Evaluation of Innovative Education Delivery and Dissemination
Sun, Yuqiang , Li, Heyi , Tekin, Aysun, Bogojevic, Marija , Heise, Katherine J., Niven, Alexander C., Flurin, Laure , Kashyap, Rahul , Finch, A.J. , Niven, Alexander, Gajic, Ognjen , Dong, Yue

Mayo Clinic

No container title available | August 3, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-708566/v1 Get It

Abstract Background CERTAIN (Checklist for Early Recognition and Treatment of Acute Illness and iNjury) has been shown to improve critical care process and patient outcomes in international ICUs with variable resources. Methods CERTAIN education program derived from this approach is designed, promoted, and implemented following the Logic model. Through the roadmap of the Logic model, we presented a dynamic, longitudinal implementation framework that had sufficient rigor yet offers flexibility to reach the need of the existing and emerging diversified medical education projects. Results Using the Logic model, the delivery of the CERTAIN education program is optimized to deliver relevant education content in various environments. During the COVID-19 outbreak, the implementational framework demonstrated that it could serve as an excellent template for effective response to global pandemics. Conclusions The Logical model is useful as a facilitation tool for planning and evaluating innovative education delivery and dissemination. The CERTAIN program provided an example for other continuous professional education projects.
Perihilar Cholangiocarcinoma – Novel Benchmark Values for Surgical and Oncological Outcomes From 24 Expert Centers
Breuer, Eva , Mizuno, Takashi , Bartsch, F. , Ratti, Francesca , Benzing, Christian , Ammar-Khodja, Noémie, Sugiura, Teiichi , Takayashiki, Tsukasa , Hessheimer, Amelia J. , Kim, Hyung Sun , Ahn, Keun Soo , Wong, Tiffany , D’Silva, Mizelle , Koerkamp, Bas Groot , Jeddou, Heithem , Ponthaud, Charles de , Ismail, Warsan, Nooijen, Lynn E. , Hidalgo-Salinas, Camila, Wagner, Kim C. , Gunasekaran, Ganesh , Higuchi, Ryota , Gleisner, Ana , Shwaartz, Chaya , Schulick, Richard D. , Yamamoto, Masakazu , Schwartz, Myron , Oldhafer, Karl J. , Prachalias, Andreas , Fusai, Giuseppe , Erdmann, Joris I. , Line, Pål‐Dag , Smoot, Rory L. , Robles, R , Boudjéma, Karim , Polak, Wojciech G. , Neumann, Ulf P. , Lo, Chung‐Mau, Kang, Koo Jeong , Park, Joon Seong , Fondevila, Constantino , Uesaka, Katsuhiko , Pratschke, Johann , Aldrighetti, Luca , Oliveira, Michelle, Lang, Hauke , Nagino, Masato , Clavien, Pierre‐Alain , Yonkus, Jennifer A. , Line, Pål Dag , Smoot, Rory L , Aldrighetti, Luca , Erdmann, Joris I , Polak, Wojciech G , Wong, Tiffany C L , De Ponthaud, Charles , Groot Koerkamp, Bas , Ratti, Francesca , Mueller, Matteo , Kim, Hyung Sun, Ruzzenente, Andrea , Ahn, Keun Soo, Wong, Tiffany, Bednarsch, Jan , Jeddou, Heithem, Lopez-Lopez, Víctor; https://orcid.org/0000-0003-1718-3352, Kontis, Elissaios A. , Higuchi, Ryota, al, et, Schulick, Richard D., Yamamoto, Masakazu, Noji, Takehiro , Hirano, Satoshi, Schwartz, Myron, Oldhafer, Karl J., Fusai, Giuseppe K., Soubrane, Olivier , Polak, Wojciech G.; id_orcid 0000-0002-3096-4893, Han, Ho Seong, Neumann, Ulf P., Lo, Chung Mau , Guglielmi, Alfredo , Ohtsuka, Masayuki , Adam, René, Pratschke, Johann, Oliveira, Michelle L. De, Gores, Gregory J.

Mayo Clinic

Annals of Surgery | August 2, 2021 | Volume: 274 | Issue: 5 | Pages: 780-788

10.1097/sla.0000000000005103 | PMID 34334638 Get It

Objective: The aim of this study was to define robust benchmark values for the surgical treatment of perihilar cholangiocarcinomas (PHC) to enable unbiased comparisons. Background: Despite ongoing efforts, postoperative mortality and morbidity remains high after complex liver surgery for PHC. Benchmark data of best achievable results in surgical PHC treatment are however still lacking. Methods: This study analyzed consecutive patients undergoing major liver surgery for PHC in 24 high-volume centers in 3 continents over the recent 5-year period (2014–2018) with a minimum follow-up of 1 year in each patient. Benchmark patients were those operated at high-volume centers (≥50 cases during the study period) without the need for vascular reconstruction due to tumor invasion, or the presence of significant co-morbidities such as severe obesity (body mass index ≥35), diabetes, or cardiovascular diseases. Benchmark cutoff values were derived from the 75th or 25th percentile of the median values of all benchmark centers. Results: Seven hundred eight (39%) of a total of 1829 consecutive patients qualified as benchmark cases. Benchmark cut-offs included: R0 resection ≥57%, postoperative liver failure (International Study Group of Liver Surgery): ≤35%; in-hospital and 3-month mortality rates ≤8% and ≤13%, respectively; 3-month grade 3 complications and the CCI: ≤70% and ≤30.5, respectively; bile leak-rate: ≤47% and 5-year overall survival of ≥39.7%. Centers operating mostly on complex cases disclosed better outcome including lower post-operative liver failure rates (4% vs 13%; P = 0.002). Centers from Asia disclosed better outcomes. Conclusion: Surgery for PHC remains associated with high morbidity and mortality with now the availability of benchmark values covering 21 outcome parameters, which may serve as key references for comparison in any future analyses of individuals, group of patients or centers.
Comparison of synchronization between left bundle branch and his bundle pacing in atrial fibrillation patients: An intra‐patient‐controlled study
Sheng, Xia , Pan, Yiwen , Yu, Chan, Wang, Bei , Zhang, Pei , Li, Jing , Zhang, Jiefang , Chen, Shiquan , Wang, Min , Sun, Yaxun , Jiang, Dongmei , Yang, Ying , Ye, Yang , Cha, Yong‐Mei , Pan, Yi-Wen , Zhang, Jie-Fang , Sun, Ya-Xun , Fu, Guo-Sheng

Mayo Clinic

Pacing and Clinical Electrophysiology | August 2, 2021 | Volume: 44 | Issue: 9 | Pages: 1523-1531

10.1111/pace.14331 | PMID 34337768 Get It

AbstractBackgroundHis bundle pacing (HBP) is a physiological pacing strategy to preserve the electrical synchrony of ventricular conduction and left ventricular (LV) function. Left bundle branch pacing (LBBP) has emerged as an alternative physiological pacing technique.ObjectiveTo evaluate cardiac electrical and mechanical synchrony comparing LBBP and HBP in patients with permanent atrial fibrillation (AF).MethodsConsecutive patients with symptomatic bradycardia and AF were enrolled from January to June of 2019. The cardiac electrical and mechanical synchrony in different pacing mode were evaluated at baseline and after implantation.ResultsBoth HBP and LBBP were performed in 20 patients. LBBP significantly widened the QRS duration compared with the intrinsic conduction (113.2 ± 14.5 vs. 96.5 ± 16.2 ms; p = .01), while HBP did not (104.5 ± 22.3 vs. 96.5 ± 16.2 ms; p = .12). Both LBBP and HBP patients had similar LV myocardial strain measurements for the mechanical synchrony evaluation without significant change compared with baseline. There was no significant difference in right ventricular synchrony measurement between LBBP and HBP. Compared to HBP, LBBP had less interventricular synchrony (IMVD, 14.7 ± 9.2 vs. 3.1 ± 12.7 ms, p < .01; Ts‐LV‐RV, 37.9 ± 10.7 vs. 18.5 ± 10.8 ms, p < .001).ConclusionsAlthough LBBP's a physiological pacing mode can achieve a similar cardiac electrical and mechanical synchronization when compared to HBP, LBBP results in modest delay in RV activation, and the clinical implication remains to be studied.
Cell fate conversion prediction by group sparse optimization method utilizing single-cell and bulk OMICs data
Qin, Jing , Yao, Jen‐Chih , Leung, Ricky Wai Tak , Zhou, Yongqiang, Qin, Yiming , Wang, Junwen , Wang, Junwen , Qin, Jing , Hu, Yaohua

Mayo Clinic

Briefings in Bioinformatics | July 21, 2021 | Volume: 22 | Issue: 6 | Pages: No page available

10.1093/bib/bbab311 | PMID 34374760 Get It

Abstract Cell fate conversion by overexpressing defined factors is a powerful tool in regenerative medicine. However, identifying key factors for cell fate conversion requires laborious experimental efforts; thus, many of such conversions have not been achieved yet. Nevertheless, cell fate conversions found in many published studies were incomplete as the expression of important gene sets could not be manipulated thoroughly. Therefore, the identification of master transcription factors for complete and efficient conversion is crucial to render this technology more applicable clinically. In the past decade, systematic analyses on various single-cell and bulk OMICs data have uncovered numerous gene regulatory mechanisms, and made it possible to predict master gene regulators during cell fate conversion. By virtue of the sparse structure of master transcription factors and the group structure of their simultaneous regulatory effects on the cell fate conversion process, this study introduces a novel computational method predicting master transcription factors based on group sparse optimization technique integrating data from multi-OMICs levels, which can be applicable to both single-cell and bulk OMICs data with a high tolerance of data sparsity. When it is compared with current prediction methods by cross-referencing published and validated master transcription factors, it possesses superior performance. In short, this method facilitates fast identification of key regulators, give raise to the possibility of higher successful conversion rate and in the hope of reducing experimental cost.
Prognostic value of minimal residual disease negativity in myeloma: combined analysis of POLLUX, CASTOR, ALCYONE, and MAIA
Miguel, Jesús F. San , Usmani, Saad Z. , Paiva, Bruno , Plesner, Torben , Hungria, Vânia , Moreau, Philippe , Mateos, María‐Victoria , Perrot, Aurore , Iida, Shinsuke , Kumar, Shaji , Donk, Niels W.C.J. van de , Sonneveld, Pieter , Spencer, Andrew , Krevvata, Maria, Heuck, Christoph, Wang, Jianping , Ukropec, Jon, Kobos, Rachel, Sun, Steven , Qi, Mia, Munshi, Nikhil C. , San-Miguel, Jesus , Paiva, Bruno , Hungria, Vania , Mateos, María-Victoria , Perrot, Aurore , Iida, Shinsuke , Kumar, Shaji K , Moreau, Philippe , Usmani, Saad , Cavo, Michèle , Weisel, Katja C , Dimopoulos, Meletios Α. , Avet‐Loiseau, Hervé , Bahlis, Nizar Jacques , Facon, Thierry T.F.

Mayo Clinic

Blood | July 21, 2021 | Volume: 139 | Issue: 6 | Pages: 835-844

10.1182/blood.2021011101 | PMID 34289038 Get It

Abstract We explored minimal residual disease (MRD) in relapsed/refractory multiple myeloma (RRMM) and transplant-ineligible (TIE) newly diagnosed multiple myeloma (NDMM) using data from 4 phase 3 studies (POLLUX, CASTOR, ALCYONE, and MAIA). Each study previously demonstrated that daratumumab-based therapies improved MRD negativity rates and reduced the risk of disease progression or death by approximately half vs standards of care. We conducted a large-scale pooled analysis for associations between patients achieving complete response or better (≥CR) with MRD-negative status and progression-free survival (PFS). MRD was assessed via next-generation sequencing (10−5 sensitivity threshold). Patient-level data were pooled from all 4 studies and for patients with TIE NDMM and patients with RRMM who received ≤2 prior lines of therapy (≤2 PL). PFS was evaluated by response and MRD status. Median follow-up (months) was 54.8 for POLLUX, 50.2 for CASTOR, 40.1 for ALCYONE, and 36.4 for MAIA. Patients who achieved ≥CR and MRD negativity had improved PFS vs those who failed to reach CR or were MRD positive (TIE NDMM and RRMM hazard ratio [HR] 0.20, P &lt; .0001; TIE NDMM and RRMM ≤2 PL HR 0.20, P &lt; .0001). This benefit occurred irrespective of therapy or disease setting. A time-varying Cox proportional hazard model confirmed that ≥CR with MRD negativity was associated with improved PFS. Daratumumab-based treatment was associated with more patients reaching ≥CR and MRD negativity. These findings represent the first large-scale analysis with robust methodology to support ≥CR with MRD negativity as a prognostic factor for PFS in RRMM and TIE NDMM. These trials were registered at www.clinicaltrials.gov as #NCT02076009, #NCT02136134, #NCT02195479, and #NCT02252172.